CA2172073A1 - Expression de proteines virales leurres sous le controle d'une sequence d'adn; applications - Google Patents
Expression de proteines virales leurres sous le controle d'une sequence d'adn; applicationsInfo
- Publication number
- CA2172073A1 CA2172073A1 CA002172073A CA2172073A CA2172073A1 CA 2172073 A1 CA2172073 A1 CA 2172073A1 CA 002172073 A CA002172073 A CA 002172073A CA 2172073 A CA2172073 A CA 2172073A CA 2172073 A1 CA2172073 A1 CA 2172073A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- nucleic acid
- vector according
- acid vector
- recombinant nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 title claims description 54
- 230000003612 virological effect Effects 0.000 title claims description 10
- 102000004169 proteins and genes Human genes 0.000 title description 16
- 239000013598 vector Substances 0.000 claims abstract description 45
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 241000700605 Viruses Species 0.000 claims abstract description 19
- 238000013518 transcription Methods 0.000 claims abstract description 18
- 230000035897 transcription Effects 0.000 claims abstract description 18
- 230000004071 biological effect Effects 0.000 claims abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 5
- 230000001419 dependent effect Effects 0.000 claims abstract description 4
- 230000010354 integration Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 69
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 210000000130 stem cell Anatomy 0.000 claims description 23
- 101710149951 Protein Tat Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 14
- 208000036142 Viral infection Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 230000009385 viral infection Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 210000002540 macrophage Anatomy 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 230000006735 deficit Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000003394 haemopoietic effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 241000699660 Mus musculus Species 0.000 description 18
- 238000011830 transgenic mouse model Methods 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 230000009261 transgenic effect Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000031886 HIV Infections Diseases 0.000 description 9
- 208000037357 HIV infectious disease Diseases 0.000 description 8
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 101150069832 CD2 gene Proteins 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710192141 Protein Nef Proteins 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 101150098170 tat gene Proteins 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241001274613 Corvus frugilegus Species 0.000 description 1
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101100273713 Homo sapiens CD2 gene Proteins 0.000 description 1
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 102100034784 Protein TANC2 Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 241000290149 Scapteriscus didactylus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- IKBJGZQVVVXCEQ-UHFFFAOYSA-N efonidipine hydrochloride Chemical compound Cl.CCO.CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 IKBJGZQVVVXCEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 101150102487 ine gene Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011856 somatic therapy Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne un vecteur d'acide nucléique recombiné destiné à l'apport d'acide nucléique à un organisme hôte comprenant une unité de transcription codant un mutant négatif transdominant d'un produit génique viral choisi notamment pour éviter un effet biologique négatif chez l'hôte sous le contrôle d'une séquence d'ADN active dans des cellules normalement infectées par un virus, laquelle est efficace pour conférer une expression de l'unité de transcription qui soit spécifique aux tissus constitutifs, indépendante du site d'intégration et dépendante du nombre de copies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9319772.1 | 1993-09-24 | ||
| GB939319772A GB9319772D0 (en) | 1993-09-24 | 1993-09-24 | Therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2172073A1 true CA2172073A1 (fr) | 1995-03-30 |
Family
ID=10742498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002172073A Abandoned CA2172073A1 (fr) | 1993-09-24 | 1994-09-26 | Expression de proteines virales leurres sous le controle d'une sequence d'adn; applications |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0725830A1 (fr) |
| JP (1) | JPH09505984A (fr) |
| AU (1) | AU697095B2 (fr) |
| CA (1) | CA2172073A1 (fr) |
| GB (1) | GB9319772D0 (fr) |
| WO (1) | WO1995008635A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2279673A1 (fr) | 1995-12-15 | 1997-06-16 | Enzo Therapeutics, Inc. | Construits possedant certaines proprietes et/ou modifiant certaines proprietes pour l'expression d'acide nucleique allogene pour utilisation therapeutique ou de diagnotisque |
| DE69716240T2 (de) * | 1996-02-12 | 2003-06-26 | Ml Lab Plc London | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten |
| US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
| GB9609261D0 (en) * | 1996-05-02 | 1996-07-03 | Isis Innovation | Gene expression in monocytes and microphages |
| CN104630149B (zh) * | 2013-11-08 | 2018-08-21 | 中国科学院广州生物医药与健康研究院 | 外源线粒体导入到哺乳动物细胞中的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8718779D0 (en) * | 1987-08-07 | 1987-09-16 | Grosveld F G | Dna sequence & expression vector |
| KR0148782B1 (ko) * | 1990-01-18 | 1998-08-17 | 더글라스 제이. 캠피온 | 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터 |
| GB9305761D0 (en) * | 1993-03-19 | 1993-05-05 | Medical Res Council | Disease model |
| GB9305759D0 (en) * | 1993-03-19 | 1993-05-05 | Medical Research Council And T | Hiv therapy method and agents |
-
1993
- 1993-09-24 GB GB939319772A patent/GB9319772D0/en active Pending
-
1994
- 1994-09-26 JP JP7509661A patent/JPH09505984A/ja active Pending
- 1994-09-26 EP EP94927720A patent/EP0725830A1/fr not_active Withdrawn
- 1994-09-26 CA CA002172073A patent/CA2172073A1/fr not_active Abandoned
- 1994-09-26 WO PCT/GB1994/002092 patent/WO1995008635A1/fr not_active Application Discontinuation
- 1994-09-26 AU AU77026/94A patent/AU697095B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU697095B2 (en) | 1998-09-24 |
| JPH09505984A (ja) | 1997-06-17 |
| GB9319772D0 (en) | 1993-11-10 |
| AU7702694A (en) | 1995-04-10 |
| WO1995008635A1 (fr) | 1995-03-30 |
| EP0725830A1 (fr) | 1996-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berry et al. | A single point mutation is the cause of the Greek form of hereditary persistence of fetal haemoglobin | |
| EP1776460A2 (fr) | Procede pour moduler l'expression genique par modification de la teneur en cpg | |
| DE60302356T2 (de) | Fusionsprotein regulatorischer/akzessorischer hiv-proteine | |
| EP0674716B1 (fr) | Vecteurs retroviraux pour le traitement des tumeurs, et lignees cellulaires les contenant | |
| WO2006013103A2 (fr) | Expression génique inductible | |
| AU696399B2 (en) | Delivery system controlled through factors associated with HIV and cell | |
| KR100402540B1 (ko) | 생체내외인성형질감염및발현용의약배합물 | |
| US5569827A (en) | Transgenic mouse for the neuronal expression of HIV gp160 | |
| Hanna et al. | HIV-1 Nef mutations abrogating downregulation of CD4 affect other Nef functions and show reduced pathogenicity in transgenic mice | |
| Hanna et al. | In vivo mutational analysis of the N-terminal region of HIV-1 Nef reveals critical motifs for the development of an AIDS-like disease in CD4C/HIV transgenic mice | |
| CA2172073A1 (fr) | Expression de proteines virales leurres sous le controle d'une sequence d'adn; applications | |
| DE69627644T2 (de) | Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie | |
| Brady et al. | Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice | |
| FR2710074A1 (fr) | Gène GRB3-3, ses variants et leurs utilisations. | |
| WO1992017211A1 (fr) | Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation | |
| US6677311B1 (en) | Inducible HSV-TK in transformed cell populations | |
| JP2997042B2 (ja) | ポリオウイルスの細胞受容体をコードするゲノム及びｃＤＮＡ配列の分子クローニング | |
| Vellutini et al. | The maedi-visna virus Tat protein induces multiorgan lymphoid hyperplasia in transgenic mice | |
| US5850001A (en) | Transgenic mouse for the neuronal expression of HIV gp160 | |
| Roosa et al. | Structure, biological activity of the upstream regulatory sequence, and conserved domains of a middle molecular mass neurofilament gene of Xenopus laevis | |
| JP2005500835A (ja) | Ｐｅｒｖスクリーニング法およびその使用 | |
| EP1551222B1 (fr) | Procede pour produire un mammifere rendu resistant a une infection par un alpha herpes virus ainsi que mammifere obtenu par la mise en oeuvre de ce procede et descendant d'un tel mammifere | |
| Gorshkova et al. | Possible mechanisms of acquisition of herpesvirus virokines | |
| Snyder et al. | Murine models of Vpr-mediated pathogenesis | |
| Berry et al. | A single point mutation is the |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |